Talphera (TLPH)
NASDAQ:TLPH
TLPH Stock Chart & Stats
$1.10
-$0.04(-6.10%)
At close: 4:00 PM EST
$1.10
-$0.04(-6.10%)
Day’s Range― - ―
52-Week Range$0.38 - $1.57
Previous CloseN/A
Volume42.81K
Average Volume (3M)2.97M
Market Cap
$38.07M
Enterprise Value$16.58M
Total Cash (Recent Filing)$20.38M
Total Debt (Recent Filing)$6.50M
Price to Earnings (P/E)―
Beta0.84
Next Earnings
May 18, 2026EPS Estimate
-0.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.06
Shares Outstanding50,049,824
10 Day Avg. Volume675,544
30 Day Avg. Volume2,969,035
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)2.84
Price to Sales (P/S)1726.72
P/FCF Ratio-4.25
Enterprise Value/Market Cap0.44
Enterprise Value/Revenue591.97
Enterprise Value/Gross Profit-14.53
Enterprise Value/Ebitda-1.46
Forecast
1Y Price Target
$3.25Price Target Upside195.45% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.29
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Established Clinical Experience With NafamostatDecades of overseas use and favorable prior clinical data for nafamostat provide confidence in the therapy’s effectiveness and could support clinician adoption.
Funding Runway And Milestone-linked FinancingCompany cash on hand is projected to fund operations through completion of the pivotal trial, and reaching the enrollment milestone makes the company eligible for an additional financing tranche to support trial completion and a regulatory filing.
Unmet Clinical Need For AnticoagulationKey opinion leaders indicate current anticoagulation for continuous dialysis is inadequate and often avoided because of systemic bleeding risk, creating demand for safer, more usable therapies.
Bears Say
Operational And Patient-severity Recruitment ChallengesLogistical challenges and the high illness severity of eligible patients have slowed enrollment, risking extended timelines and higher trial costs.
Restrictive Eligibility Criteria Limiting EnrollmentVery restrictive clotting and bleeding eligibility criteria are excluding a large number of patients, which may impede trial progress and slow data availability.
Talphera News
TLPH FAQ
What was Talphera’s price range in the past 12 months?
Talphera lowest stock price was $0.38 and its highest was $1.57 in the past 12 months.
What is Talphera’s market cap?
Talphera’s market cap is $38.07M.
When is Talphera’s upcoming earnings report date?
Talphera’s upcoming earnings report date is May 18, 2026 which is in 34 days.
How were Talphera’s earnings last quarter?
Talphera released its earnings results on Mar 23, 2026. The company reported -$0.06 earnings per share for the quarter, beating the consensus estimate of -$0.075 by $0.015.
Is Talphera overvalued?
According to Wall Street analysts Talphera’s price is currently Undervalued.
Does Talphera pay dividends?
Talphera does not currently pay dividends.
What is Talphera’s EPS estimate?
Talphera’s EPS estimate is -0.07.
How many shares outstanding does Talphera have?
Talphera has 50,049,824 shares outstanding.
What happened to Talphera’s price movement after its last earnings report?
Talphera reported an EPS of -$0.06 in its last earnings report, beating expectations of -$0.075. Following the earnings report the stock price went down -3.726%.
Which hedge fund is a major shareholder of Talphera?
Currently, no hedge funds are holding shares in TLPH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Talphera Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$3.25 (195.45% Upside)
$3.25 (195.45% Upside)
Insider Transactions
Bought Shares
Worth $178.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▼ 0.7%
Last 30 Days ▲ 0.3%
Last 30 Days ▲ 0.3%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-7.75%
12-Months-Change
Fundamentals
Return on Equity
-118.01%
Trailing 12-Months
Asset Growth
62.97%
Trailing 12-Months
Company Description
Talphera
Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, an anti-inflammatory and antiviral potential for the treatment of multiple conditions, including COVID-19, disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis; Fedsyra, a pre-filled ephedrine syringe; and PFS-02, a pre-filled phenylephrine syringe. The company was formerly known as AcelRx Pharmaceuticals, Inc. and changed its name to Talphera, Inc. in January 2024. Talphera, Inc. was incorporated in 2005 and is headquartered in San Mateo, California.
TLPH Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a mix of positive and negative aspects. While there are significant achievements in financial stability, regulatory clarity, and enrollment progress, the delays in site activation and enrollment challenges pose notable concerns.View all TLPH earnings summariesTLPH Stock 12 Month Forecast
Average Price Target
$3.25
▲(195.45% Upside)
Technical Analysis
Ownership Overview
6.18% Insiders
1.26% Mutual Funds
41.28% Other Institutional Investors
50.32% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---